logo.jpg
Capital Increase in Genmab as a Result of Employee Warrant Exercise
September 21, 2021 14:22 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; September 21, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 3,969 shares as a consequence of the exercise of employee warrants. The...
logo.jpg
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
September 20, 2021 17:00 ET | Genmab A/S
TIVDAK is a First-in-Class Antibody-Drug Conjugate Directed to Tissue Factor, a Protein Expressed on Cervical Cancer CellsNew Monotherapy Approved for Use in a Cancer with Limited Treatment Options ...
logo.jpg
Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
September 19, 2021 11:30 ET | Genmab A/S
Media Release Tisotumab Vedotin in Combination with Carboplatin Showed Encouraging, Durable Anti-Tumor Activity as First-Line Treatment Tisotumab Vedotin in Combination with Pembrolizumab Showed...
logo.jpg
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
September 09, 2021 07:00 ET | Genmab A/S
Media Release Phase 1/2 first-in-human (FIH) dose escalation and cohort expansion trial evaluating safety and preliminary efficacy of epcoritamab in patients with relapsed/refractory B-cell...
logo.jpg
Genmab to Present at Morgan Stanley 19th Annual Global Healthcare Conference
August 27, 2021 04:42 ET | Genmab A/S
Media ReleaseCopenhagen, Denmark, 27 August, 2021 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D. will participate in a virtual fireside chat at the Morgan Stanley...
logo.jpg
Capital Increase in Genmab as a Result of Employee Warrant Exercise
August 17, 2021 14:51 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 17, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 12,370 shares as a consequence of the exercise of employee warrants. The...
logo.jpg
Genmab Announces Financial Results for the First Half of 2021
August 11, 2021 11:01 ET | Genmab A/S
August 11, 2021; Copenhagen, Denmark; Interim Report for the First Half of 2021 Highlights The U.S. FDA accepted for Priority Review the tisotumab vedotin Biologics License Application...
logo.jpg
Major Shareholder Announcement
July 21, 2021 12:58 ET | Genmab A/S
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 21, 2021 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
logo.jpg
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021
July 21, 2021 06:31 ET | Genmab A/S
Company Announcement Net sales of DARZALEX® in the second quarter of 2021 totaled USD 1,433 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark;...
logo.jpg
Capital Increase in Genmab as a Result of Employee Warrant Exercise
July 06, 2021 14:04 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; July 06, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,974 shares as a consequence of the exercise of employee warrants. The...